| Approved? (Admin-only) |
|
|---|---|
| Opportunity Type | Pre-Release |
| Funding Opportunity Posted By | DOW |
| Component | DHA - CDMRP |
| Funding Opportunity Title | Duchenne Muscular Dystrophy Research Program |
| Link to Funding Opportunity | health.mil |
| Funding Opportunity Short Description | To support innovative, high-impact research with clinical relevance that will preserve and improve the function and quality of life across the lifespan of all individuals with Duchenne muscular dystrophy. |
| Funding Opportunity Category | Health and Biomedical Technologies |
| Important Dates | |
| Funding Details | |
| Required Registrations |
|
| Funding Opportunity Full Description | Two Award Mechanisms (1) Idea Development Award (2) Clinical/Translational Research Award The FY26 Defense Appropriations Act provides funding for the DMDRP to support innovative, high-impact research with clinical relevance that will preserve and improve the function and quality of life across the lifespan of all individuals with Duchenne muscular dystrophy. As part of the DHA R&D-MRDC, the CDMRP is the program office managing these anticipated FY26 funding opportunities. The DMDRP provides the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY26 funding opportunities. Investigators should not construe this pre-announcement as an obligation or promise by the government. The CDMRP will post FY26 DMDRP funding opportunity announcements on the Grants.gov website. Once released, the funding opportunity announcements will include pre-application and application deadlines. Applications submitted to the FY26 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that focus on the primary pathology of DMD. Therapies that will be efficacious across the lifespan, including infants, toddlers, and non-ambulatory individuals are strongly encouraged. Applications submitted to the FY26 DMDRP Clinical/Translational Research Award must address at least one of the following focus areas: For applications proposing preclinical translational research Extension or expansion of existing preclinical data in support of Investigational New Drug (IND) application-enabling studies Prospective, real world data, or post-market studies for combination or sequential therapies and/or long-term safety and efficacy studies |
